Wegovy vs Zepbound: Which Is Better for Weight Loss?

Wegovy and Zepbound are two of the most-prescribed prescription medications for chronic weight management, and they consistently dominate online interest — weight-loss compounds now account for roughly 60% of all peptide-related search traffic. Both are injectable peptide-based drugs that act on gut-hormone pathways to reduce appetite, slow gastric emptying, and improve metabolic regulation. Despite belonging to the same broad class of GLP-1 receptor agonists, they are distinct molecules with different manufacturers, mechanisms, and clinical track records.

Wegovy is the brand name for semaglutide 2.4 mg, manufactured by Novo Nordisk. The same molecule is sold at lower doses as Ozempic for type 2 diabetes. Semaglutide first received FDA approval for diabetes in 2017, and the higher-dose Wegovy formulation was approved specifically for chronic weight management in June 2021. It is administered as a once-weekly subcutaneous injection, titrated up over roughly 16 weeks to a maintenance dose of 2.4 mg.

Zepbound is the brand name for tirzepatide, manufactured by Eli Lilly. The identical molecule is sold as Mounjaro for type 2 diabetes. Tirzepatide was approved for diabetes in 2022, and Zepbound received FDA approval for chronic weight management in November 2023, making it the newer entrant. It is also a once-weekly subcutaneous injection, available in maintenance doses of 5 mg, 10 mg, and 15 mg.

Both drugs are indicated for adults with obesity (a body mass index of 30 or higher) or with overweight (a BMI of 27 or higher) accompanied by at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes. They are intended to be used alongside a reduced-calorie diet and increased physical activity — not as standalone solutions. To understand the broader biology behind these molecules, see our primer on what peptides are.

This article is for educational purposes only and is not medical advice. Wegovy and Zepbound are prescription medications; consult a qualified healthcare professional before starting, stopping, or switching any treatment.

The most important biological distinction between the two drugs lies in the receptors they activate. Semaglutide (Wegovy) is a single-agonist molecule: it binds and activates the GLP-1 (glucagon-like peptide-1) receptor. GLP-1 is an incretin hormone released by the gut after eating. Activating its receptor enhances glucose-dependent insulin secretion, slows gastric emptying, and acts on appetite centers in the hypothalamus to increase satiety and reduce food intake.

Tirzepatide (Zepbound) is a dual agonist: it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second incretin hormone, and the combined stimulation of both pathways appears to produce additive — possibly synergistic — effects on appetite suppression and energy balance. This dual mechanism is the leading hypothesis for why tirzepatide tends to outperform semaglutide on weight outcomes in clinical trials.

From a pharmacokinetic standpoint, both molecules are engineered for a long half-life of around five days, which is what makes once-weekly dosing possible. Each carries a fatty-acid chain that promotes binding to albumin in the blood, slowing renal clearance and enzymatic degradation. Without such modifications, native peptides are typically cleared within minutes to hours, so these structural tweaks are central to their practicality as therapeutics.

It is worth noting that the role of GIP agonism in weight loss was historically debated, and the precise contribution of the GIP component to tirzepatide's efficacy is still an area of active research. What is clinically established is the net outcome rather than a fully resolved mechanistic explanation. This is a recurring theme in metabolic pharmacology: observed efficacy often precedes a complete mechanistic understanding.

Because both drugs slow gastric emptying and act centrally on appetite, they share a similar overall side-effect profile dominated by gastrointestinal symptoms — a point we return to below. The mechanistic overlap also means that the two drugs are not meant to be combined; doing so would compound risk without established benefit.

The clearest signal in this comparison comes from clinical trial data. In the pivotal STEP 1 trial (Wilding et al., 2021), adults without diabetes who received semaglutide 2.4 mg lost an average of approximately 14.9% of their body weight over 68 weeks, compared with about 2.4% in the placebo group. STEP 1 established Wegovy as a landmark in obesity pharmacotherapy, roughly doubling the weight loss seen with earlier GLP-1 agents.

The SURMOUNT-1 trial (Jastreboff et al., 2022) evaluated tirzepatide in adults with obesity but without diabetes over 72 weeks. Mean weight reduction was dose-dependent: roughly 15% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg. These figures placed tirzepatide's top doses in a range previously associated with bariatric surgery, and they consistently exceeded the STEP 1 benchmark for semaglutide.

Cross-trial comparisons are imperfect because trial populations and protocols differ. That limitation was directly addressed by SURMOUNT-5 (Aronne et al., 2025), the first large head-to-head trial pitting tirzepatide directly against semaglutide 2.4 mg in adults with obesity and without diabetes. Over 72 weeks, participants on tirzepatide lost about 20.2% of body weight versus 13.7% on semaglutide — a statistically significant advantage for tirzepatide of roughly 6–7 percentage points.

SURMOUNT-5 also reported that a substantially larger proportion of tirzepatide users achieved deep weight-loss thresholds — for example, losing 25% or more of their body weight. This consistency across both indirect and direct comparisons makes tirzepatide (Zepbound) the more effective option on average for pure weight reduction at maximum tolerated doses.

That said, "more weight loss on average" does not mean Zepbound is better for every individual. Response varies considerably from person to person, and many people reach their personal weight goals successfully on semaglutide. Tolerability, cost, access, and comorbidities can matter more than a few percentage points of average efficacy. Average trial outcomes describe populations, not the experience of any single patient.

The table below summarizes the key practical and clinical differences between Wegovy and Zepbound. Figures are approximate and drawn from pivotal trials and US labeling; actual cost and availability vary by country, insurer, and pharmacy.

As the table shows, the two drugs are structurally similar in how they are used — both are weekly self-injections requiring a gradual dose escalation — but they diverge most clearly on mechanism, dose flexibility, and average efficacy. Zepbound's three maintenance doses give clinicians more room to balance efficacy against tolerability, whereas Wegovy has a single target maintenance dose.

Prices are illustrative US list prices before insurance or manufacturer savings programs and change frequently. Always confirm current pricing and coverage with your pharmacy and insurer.

Because both drugs act on the same incretin pathways and slow gastric emptying, their side-effect profiles are strikingly similar. The most common adverse events for both are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. These symptoms are usually mild to moderate, tend to appear during dose escalation, and often diminish as the body adapts over several weeks.

Slow, deliberate dose titration is the primary strategy used to limit these effects. Starting low and increasing gradually — over roughly 16 weeks for Wegovy and in steps for Zepbound — gives the gut time to adjust. In the SURMOUNT-5 head-to-head trial, the overall rates of gastrointestinal side effects were broadly comparable between the two drugs, and discontinuation rates due to adverse events were low and similar for both.

Both medications carry a boxed warning regarding the risk of thyroid C-cell tumors, based on findings in rodents; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other less common but serious risks shared by both include pancreatitis, gallbladder disease, kidney injury related to dehydration from vomiting or diarrhea, and the potential to worsen diabetic retinopathy in susceptible patients.

There are also practical safety considerations that apply to both drugs. Because they slow gastric emptying, there have been reports of retained gastric contents during surgery or endoscopy under anesthesia, prompting evolving guidance about pausing these medications before procedures. Both drugs may also affect the absorption of oral medications and should be used cautiously with insulin or sulfonylureas because of hypoglycemia risk.

No medication is "completely safe," and the decision to use either drug requires weighing benefits against these risks for each individual. A healthcare professional can review your medical history, current medications, and risk factors before prescribing. This section is educational and does not replace personalized medical advice.

Cost is frequently the deciding factor in the real world, even when efficacy data favor one drug. In the United States, both Wegovy and Zepbound carry list prices in the rough range of $1,000–$1,350 per month before insurance. The actual amount a person pays depends heavily on insurance coverage, manufacturer savings cards, and whether the drug is prescribed for obesity (often poorly covered) versus an approved comorbidity.

Insurance coverage for anti-obesity medications remains inconsistent. Many commercial plans cover these drugs only with prior authorization or step-therapy requirements, and a number of plans exclude weight-loss indications entirely. Both manufacturers offer savings programs that can substantially reduce out-of-pocket costs for eligible, commercially insured patients, and both have introduced lower-cost self-pay vial options for those without coverage.

Availability has been a major issue for both drugs. Surging demand — tirzepatide alone now generates over a million searches per month, the single most-searched peptide term — led to periodic shortages of various doses. During shortage periods, compounded versions of semaglutide and tirzepatide proliferated through compounding pharmacies and telehealth platforms. These compounded products are not FDA-approved, may vary in quality and concentration, and have been the subject of regulatory warnings.

The compounding landscape is also legally fluid. As the FDA declares shortages resolved, the legal basis for large-scale compounding of these molecules narrows or disappears, which can abruptly change access and pricing for people who relied on compounded sources. This makes compounded products an unreliable basis for long-term treatment planning.

From a pure value standpoint, Zepbound's greater average efficacy may make it more cost-effective per percentage point of weight lost, but this calculus collapses if one drug is covered by insurance and the other is not. We strongly advise verifying current coverage, list prices, and shortage status directly with your insurer and pharmacy, and being cautious about unapproved compounded products. See our medical disclaimer for more on these limitations.

Switching between the two drugs is common and clinically feasible, and people do it for several reasons: a weight-loss plateau on one drug, intolerable side effects, insurance changes, or shortages affecting a particular product. Because both molecules target the GLP-1 pathway, the body is not starting from zero when transitioning — but they are not interchangeable on a milligram-for-milligram basis, and a switch should always be planned with a prescriber.

A frequent scenario is switching from Wegovy to Zepbound in pursuit of greater weight loss, especially for someone who has stalled on semaglutide 2.4 mg. In this direction, clinicians typically do not restart at the lowest tirzepatide dose from scratch, because the patient already has some incretin tolerance, but they still escalate carefully to manage gastrointestinal effects. The reverse switch — from Zepbound to Wegovy — may happen due to coverage, supply, or tolerability, and likewise requires a tailored titration plan.

There is no universally standardized cross-titration protocol, and dose-equivalence between the two drugs is approximate at best. This is precisely why self-directed switching is discouraged. Abruptly substituting one for the other at an arbitrary dose can either trigger a wave of nausea and vomiting (if the new dose is functionally too high) or cause appetite rebound and weight regain (if it is too low).

Timing also matters. Because both drugs are weekly injections with multi-day half-lives, a switch is generally initiated around the time the next dose would be due, rather than overlapping the two medications. Overlapping is avoided because stacking two incretin agonists offers no proven benefit and meaningfully increases the risk of side effects.

If you are considering a switch, treat it as a clinical decision rather than a casual swap. A prescriber can map an appropriate starting dose, set an escalation schedule, and monitor for side effects and efficacy. For readers building broader background knowledge, our peptide glossary explains many of the terms used in this context. Never switch prescription medications without professional guidance.

If the only question were average weight loss at maximum tolerated dose, the trial evidence points to Zepbound (tirzepatide). Both indirect comparisons across the SURMOUNT and STEP programs and the direct SURMOUNT-5 head-to-head trial show tirzepatide producing greater mean reductions in body weight. Its dual GIP/GLP-1 mechanism and flexible dosing also give clinicians more tools to optimize results.

However, "better on average" is not the same as "better for you." Wegovy (semaglutide) remains a highly effective medication with a longer real-world track record, extensive cardiovascular outcome data, and proven results for millions of patients. For many people, the deciding factors will be which drug their insurance covers, which is in stock at their pharmacy, how their body tolerates each, and what their prescriber recommends based on their full medical picture.

Individual response is genuinely variable. Some people who tolerate semaglutide poorly do better on tirzepatide, and vice versa. Comorbidities matter too: a patient's history of cardiovascular disease, type 2 diabetes, kidney function, or gastrointestinal sensitivity can tip the balance toward one drug independent of the headline efficacy numbers. Neither drug is a substitute for sustained changes to diet, activity, and sleep.

It is also worth setting realistic expectations about durability. Both drugs are intended for long-term, ongoing use; observational and trial data indicate that stopping either medication is commonly followed by partial weight regain. This means cost and access are not one-time considerations but recurring ones, which can ultimately matter more than a few percentage points of average efficacy.

The most reliable path is a shared decision with a qualified healthcare professional who can weigh the SURMOUNT-5 efficacy gap against your coverage, tolerability, and health history. For foundational context on this drug class, revisit our GLP-1 guide. This article is for educational purposes only and is not a substitute for professional medical advice; always consult a licensed clinician before starting or changing treatment.